Syndesi was a biopharmaceutical company founded in December 2017 and based in Belgium. In March 2022 Syndesi was acquired by AbbVie for $130 million up front and additional milestone payments potentially adding $870 million to the deal. Syndesi pioneered the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi’s unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission.

Syndesi was created through a partnership between a syndicate of investors, including V-Bio Ventures, and UCB who had initially discovered the SV2A modulators. Syndesi’s Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from V-Bio Ventures, Johnson & Johnson Innovation – JJDC, SRIW (Société Régionale d’Investissement de Wallonie), Vives Fund, and UCB Ventures.